| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial
|
Kennedy, Glen A
|
|
2014
|
15 |
13 |
p. 1451-1459
|
artikel
|
| 2 |
Addressing the burden of cancer in the Gulf
|
The Lancet Oncology,
|
|
2014
|
15 |
13 |
p. 1407
|
artikel
|
| 3 |
Adjuvant trastuzumab improves survival in early breast cancer
|
Brower, Vicki
|
|
2014
|
15 |
13 |
p. e589
|
artikel
|
| 4 |
An oral proteasome inhibitor for multiple myeloma
|
Pratt, Guy
|
|
2014
|
15 |
13 |
p. 1417-1418
|
artikel
|
| 5 |
A practice-changing step forward in germ-cell cancer?
|
Lorch, Anja
|
|
2014
|
15 |
13 |
p. 1409-1410
|
artikel
|
| 6 |
Australian HPV vaccination programme yields results
|
Howe, Megan
|
|
2014
|
15 |
13 |
p. e591
|
artikel
|
| 7 |
Blurring of boundaries in the doctor–patient relationship
|
Fallowfield, Lesley
|
|
2014
|
15 |
13 |
p. 1423-1424
|
artikel
|
| 8 |
Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes
|
Grosse, Yann
|
|
2014
|
15 |
13 |
p. 1427-1428
|
artikel
|
| 9 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial
|
Sestak, Ivana
|
|
2014
|
15 |
13 |
p. 1460-1468
|
artikel
|
| 10 |
Chromoplexy and hypoxic microenvironment drives prostate cancer
|
Ballas, Leslie K
|
|
2014
|
15 |
13 |
p. 1419-1421
|
artikel
|
| 11 |
CIN excision and preterm birth risk
|
Burki, Talha Khan
|
|
2014
|
15 |
13 |
p. e592
|
artikel
|
| 12 |
Combination boosts survival for metastatic melanoma
|
Tanday, Sanjay
|
|
2014
|
15 |
13 |
p. e592
|
artikel
|
| 13 |
Correction to Lancet Oncol 2014; 15: 310, 311
|
|
|
2014
|
15 |
13 |
p. e587
|
artikel
|
| 14 |
Correction to Lancet Oncol 2014; 15: 1464
|
|
|
2014
|
15 |
13 |
p. e587
|
artikel
|
| 15 |
Correction to Lancet Oncol 2014; 15: 1280
|
|
|
2014
|
15 |
13 |
p. e587
|
artikel
|
| 16 |
Correction to Lancet Oncol 2014; 15: e395–403
|
|
|
2014
|
15 |
13 |
p. e587
|
artikel
|
| 17 |
Correction to Lancet Oncol 2014; 15: e591
|
|
|
2014
|
15 |
13 |
p. e587
|
artikel
|
| 18 |
CRC risk knowledge does not affect screening compliance
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
13 |
p. e588
|
artikel
|
| 19 |
Curing Cancer
|
Norton, Emma
|
|
2014
|
15 |
13 |
p. 1432
|
artikel
|
| 20 |
Dacomitinib: another option for EGFR-mutant lung cancer?
|
Mitsudomi, Tetsuya
|
|
2014
|
15 |
13 |
p. 1408-1409
|
artikel
|
| 21 |
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
|
Jänne, Pasi A
|
|
2014
|
15 |
13 |
p. 1433-1441
|
artikel
|
| 22 |
Does cilengitide deserve another chance?
|
Tucci, Marco
|
|
2014
|
15 |
13 |
p. e584-e585
|
artikel
|
| 23 |
Does cilengitide deserve another chance?–Authors' reply
|
Stupp, Roger
|
|
2014
|
15 |
13 |
p. e585-e586
|
artikel
|
| 24 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials
|
Schmoll, Hans-Joachim
|
|
2014
|
15 |
13 |
p. 1481-1492
|
artikel
|
| 25 |
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
|
Brewster, Abenaa M
|
|
2014
|
15 |
13 |
p. e625-e634
|
artikel
|
| 26 |
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
|
Franz, David Neal
|
|
2014
|
15 |
13 |
p. 1513-1520
|
artikel
|
| 27 |
Faith and medicine: goodbye cancer
|
Morgan, Jules
|
|
2014
|
15 |
13 |
p. 1431-1432
|
artikel
|
| 28 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3
|
Pietrantonio, Filippo
|
|
2014
|
15 |
13 |
p. e581
|
artikel
|
| 29 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3
|
Petrelli, Fausto
|
|
2014
|
15 |
13 |
p. e581-e582
|
artikel
|
| 30 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3
|
Price, Timothy J
|
|
2014
|
15 |
13 |
p. e582-e583
|
artikel
|
| 31 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3–Authors' reply
|
Heinemann, Volker
|
|
2014
|
15 |
13 |
p. e583-e584
|
artikel
|
| 32 |
FOLFOXIRI and bevacizumab in metastatic colorectal cancer
|
Rahman, Ahmadur
|
|
2014
|
15 |
13 |
p. e590
|
artikel
|
| 33 |
Global uptake of BHGI guidelines for breast cancer
|
Echavarria, Maria Isabel
|
|
2014
|
15 |
13 |
p. 1421-1423
|
artikel
|
| 34 |
Harnessing GVHD by interleukin-6 receptor blockade
|
Finke, Jürgen
|
|
2014
|
15 |
13 |
p. 1411-1412
|
artikel
|
| 35 |
High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer
|
De Ruysscher, Dirk
|
|
2014
|
15 |
13 |
p. e620-e624
|
artikel
|
| 36 |
How can we improve adjuvant chemotherapy for colon cancer?
|
Boku, Narikazu
|
|
2014
|
15 |
13 |
p. 1413-1415
|
artikel
|
| 37 |
Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria
|
Ruhnke, Markus
|
|
2014
|
15 |
13 |
p. e606-e619
|
artikel
|
| 38 |
Late detection of lung cancer
|
Burki, Talha Khan
|
|
2014
|
15 |
13 |
p. e590
|
artikel
|
| 39 |
Life Itself
|
van Dorn, Aaron
|
|
2014
|
15 |
13 |
p. 1429-1430
|
artikel
|
| 40 |
NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Tucker, Helen
|
|
2014
|
15 |
13 |
p. 1425-1426
|
artikel
|
| 41 |
Non-coding RNAs as biomarkers for metastatic prostate cancer
|
Veltri, William Robert
|
|
2014
|
15 |
13 |
p. 1412-1413
|
artikel
|
| 42 |
Not quite falling off a cliff
|
Morgan, Jules
|
|
2014
|
15 |
13 |
p. 1431
|
artikel
|
| 43 |
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
|
Fizazi, Karim
|
|
2014
|
15 |
13 |
p. 1442-1450
|
artikel
|
| 44 |
Predicting pathological complete response in breast cancer early
|
Groheux, David
|
|
2014
|
15 |
13 |
p. 1415-1416
|
artikel
|
| 45 |
Prostate cancer services vary in England and Wales
|
Mayor, Susan
|
|
2014
|
15 |
13 |
p. e593
|
artikel
|
| 46 |
PSA test not recommended by Canadian Task Force
|
Tanday, Sanjay
|
|
2014
|
15 |
13 |
p. e589
|
artikel
|
| 47 |
Radiotherapy for testicular cancer increases gastric cancer risk
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
13 |
p. e593
|
artikel
|
| 48 |
Regulatory and clinical considerations for biosimilar oncology drugs
|
Bennett, Charles L
|
|
2014
|
15 |
13 |
p. e594-e605
|
artikel
|
| 49 |
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
|
Prensner, John R
|
|
2014
|
15 |
13 |
p. 1469-1480
|
artikel
|
| 50 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
|
Kumar, Shaji K
|
|
2014
|
15 |
13 |
p. 1503-1512
|
artikel
|
| 51 |
The Iceberg
|
Russill, Katherine
|
|
2014
|
15 |
13 |
p. 1430-1431
|
artikel
|
| 52 |
The mTOR inhibitor revolution rolls on
|
Northrup, Hope
|
|
2014
|
15 |
13 |
p. 1418-1419
|
artikel
|
| 53 |
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
|
Lalonde, Emilie
|
|
2014
|
15 |
13 |
p. 1521-1532
|
artikel
|
| 54 |
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
|
Coudert, Bruno
|
|
2014
|
15 |
13 |
p. 1493-1502
|
artikel
|
| 55 |
US hospitals object to changes in Genentech drug distribution
|
Furlow, Bryant
|
|
2014
|
15 |
13 |
p. e591
|
artikel
|
| 56 |
What We Did On Our Holiday
|
Mohammadi, Dara
|
|
2014
|
15 |
13 |
p. 1429
|
artikel
|
| 57 |
WHO Framework Convention on Tobacco Control conference
|
Burki, Talha Khan
|
|
2014
|
15 |
13 |
p. e588
|
artikel
|
Tijdschrift beschrijving